Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Bruins Live

3

4

Final OT

Patriots Live

17

16

Final

MARKET MOVERS

Dendreon expects slowdown in sales

istockphoto.com

Dendreon makes Provenge, which is designed to induce an immune response against prostate cancer.

Continue reading below

Dendreon Corp. expects first-quarter sales to be slower than in the fourth quarter, when sales of its prostate cancer treatment Provenge were $77 million. The Seattle drug maker said first-quarter revenue growth for the drug would be in the low single digits. Fourth-quarter net income was $38.1 million, or 26 cents a share. Profit excluding some items was 45 cents a share. Analysts expected 60 cents.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com